All In Biotech

Drug Trial Radar · NCT06717269

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

A Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Tolerability of NX-5948 Tablets Following Single and Multiple Ascending Doses, the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, the Effect of NX-5948 on the QT Interval, the Effect of Food on the Pharmacokinetics of NX-5948, Drug-Drug Interactions With NX-5948, and the Intra-Subject Variability of the Bioavailability of NX-5948 Capsules

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

223

Actual

Start

Nov 30, 2024

Primary completion

May 1, 2026

Study completion May 1, 2026

Sponsor

Lead sponsor
Nurix Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multiple part, multiple cohort study evaluating single and multiple ascending doses, relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.

Conditions

  • Healthy Volunteer

Interventions

  • NX-5948Drug

    Administered orally in tablet or capsule form

  • EsomeprazoleDrug

    Administered orally in capsule form

  • PlaceboDrug

    Administered orally matching NX-5948 tablets

  • FamotidineDrug

    Administered orally in tablet form

  • MidazolamDrug

    Administered orally in syrup form

  • DigoxinDrug

    Administered orally in tablet form

  • RosuvastatinDrug

    Administered orally in tablet form

  • QuinidineDrug

    Administered orally in tablet form

  • NX-5948Drug

    Administered in capsule form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948Time frame: 9 weeks
  2. Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf): NX-5948Time frame: 9 weeks
  3. Maximum observed concentration (Cmax): NX-5948Time frame: 9 weeks
  4. AUC0-t: Midazolam, rosuvastatin, or digoxinTime frame: 9 weeks
  5. AUC0-inf: Midazolam, rosuvastatin, or digoxinTime frame: 9 weeks
  6. Cmax: Midazolam, rosuvastatin, or digoxinTime frame: 9 weeks
  7. Placebo-corrected change from baseline QT interval (QTc) as measured by electrocardiogramTime frame: Baseline, 9 weeks
  8. Number of participants with treatment-emergent adverse eventsTime frame: Up to 10 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Phoenix, Arizona

  • Celerion

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.